U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

The days of cheaper alternatives to popular weight-loss drugs like Wegovy and Zepbound are over for some ... that are not exact copies are still legal. A federal judge March 5 denied a request ...

Tirzepatide: The shortage of tirzepatide injection products (Mounjaro and Zepbound) was previously determined to be resolved as of December 19, 2024. Legal Challenges to the FDA’s Decision to ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are ...

the FDA said all doses of Mounjaro and Zepbound were readily available and took the drug off its shortage list, spelling the end for mass compounding of the drug. After months of legal challenges ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls’ ...

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

Supply issues finally started to ease late in 2024, as compounded semaglutide — "copycats" of the patented stuff like Ozempic and Zepbound — began to flood the market when the FDA temporarily ...

President Trump wants to bring pharmaceutical manufacturing back to the United States. Experts warn that tariffs could result ...